ACHV - Achieve gets US patent for new cytisinicline formulation linked to smoking cessation

• Achieve Life Sciences ( NASDAQ: ACHV ) said the U.S. Patent and Trademark Office (USPTO) issued Patent No. 11,459,328 covering the mesylate salt formulation of cytisinicline and the process for its development.
• The company noted that it is currently conducting a phase 3 trial, dubbed ORCA-3, for smoking cessation and a phase 2 study called ORCA-V1 evaluating cytisinicline for e-cigarette cessation.
• Achieve expects topline data from both trials in Q2 2023.
• "Continuing to expand our intellectual patent portfolio around cytisinicline further protects our nicotine dependence franchise," said Achieve CEO John Bencich.
• Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor, according to the company.

For further details see: